Vedolizumab — Membership Pricing

Other medications in Digestive Health

• Adalimumab
• Alosetron
• Bisacodyl
• Budesonide (Crohn)
• Certolizumab
• Cholestyramine (GI)
• Dexlansoprazole
• Docusate

About Vedolizumab

Living with inflammatory bowel disease (IBD) can be challenging, and managing its treatment, like vedolizumab (Entyvio®), often comes with significant costs. At TheDrugClub, we believe in making essential medications more accessible. Our membership program is designed to help you find substantial savings, ensuring you can focus on your health without the added financial strain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Vedolizumab is approved for (FDA label)

ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: April 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Vedolizumab (FDA label)

Intravenous infusion For injection: 300 mg vedolizumab in a single-dose vial. ( 3 ) Subcutaneous injection Injection: 108 mg/0.68 mL solution in a single-dose prefilled syringe with needle safety device. ( 3 ) Injection: 108 mg/0.68 mL solution in a single-dose prefilled pen (ENTYVIO PEN). ( 3 ) Intravenous Infusion For injection: 300 mg of vedolizumab as a white to off-white lyophilized cake in a single-dose vial for reconstitution. Subcutaneous Injection Injection: 108 mg/0.68 mL vedolizumab as a clear to moderately opalescent, colorless to slightly yellow solution in a single-dose prefilled syringe with needle safety device. Injection: 108 mg/0.68 mL vedolizumab as a clear to moderately opalescent, colorless to slightly yellow solution in a single-dose prefilled pen (ENTYVIO PEN).

Source: FDA prescribing information (DailyMed). Set ID: 6e94621c-1a95-4af9-98d1-52b9e6f1949c. SPL document ID: 266293d6-dd28-4e38-81c2-4f518d95ef5d. Label effective date: April 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Vedolizumab (FDA label)

The following topics are also discussed in detail in the Warnings and Precautions section: Infusion-Related Reactions and Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Infections [see Warnings and Precautions (5.2) ] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions (5.3) ] Liver Injury [see Warnings and Precautions (5.4) ] Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) are: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities. ( 6.1 ) Adverse reactions with subcutaneous ENTYVIO are similar to those reported with intravenous ENTYVIO with the exception of injection site reactions reported with subcutaneous ENTYVIO. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 6e94621c-1a95-4af9-98d1-52b9e6f1949c. SPL document ID: 266293d6-dd28-4e38-81c2-4f518d95ef5d. Label effective date: April 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Vedolizumab (FDA label)

ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients (such as dyspnea, bronchospasm, urticaria, flushing, rash and increased heart rate) [see Warnings and Precautions (5.1) ] . Patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 6e94621c-1a95-4af9-98d1-52b9e6f1949c. SPL document ID: 266293d6-dd28-4e38-81c2-4f518d95ef5d. Label effective date: April 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Vedolizumab (FDA label)

Infusion-Related Reactions and Hypersensitivity Reactions : Discontinue ENTYVIO and initiate appropriate treatment if serious reactions occur. ( 5.1 ) Infections : Treatment with ENTYVIO should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. If a serious infection develops, ENTYVIO should not be administered until the infection resolves. ( 5.2 ) Progressive Multifocal Leukoencephalopathy (PML) : Although unlikely, a risk of PML cannot be ruled out.

Source: FDA prescribing information (DailyMed). Set ID: 6e94621c-1a95-4af9-98d1-52b9e6f1949c. SPL document ID: 266293d6-dd28-4e38-81c2-4f518d95ef5d. Label effective date: April 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Vedolizumab (FDA label)

7.1 Natalizumab Products Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products. 7.2 TNF Blockers Because of the potential for increased risk of infections, avoid the concomitant use of ENTYVIO with TNF blockers. 7.3 CYP450 Substrates The formation of CYP450 enzymes may be suppressed by increased levels of certain cytokines (e.g., IL-6, IL-10, TNFα, IFN) during chronic inflammation. Therefore, use of ENTYVIO may normalize the formation of CYP450 enzymes by modulating the underlying disease. Upon initiation or discontinuation of ENTYVIO in patients treated with CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP substrate as needed. See the prescribing information of specific CYP substrates.

Source: FDA prescribing information (DailyMed). Set ID: 6e94621c-1a95-4af9-98d1-52b9e6f1949c. SPL document ID: 266293d6-dd28-4e38-81c2-4f518d95ef5d. Label effective date: April 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.